Policy & Regulation
LENZ Therapeutics advances VIZZ regulatory expansion with UK submission for presbyopia treatment
20 April 2026 - US pharmaceutical company LENZ Therapeutics Inc (Nasdaq:LENZ) announced on Monday that it has submitted a marketing authorisation application (MAA) to the United Kingdom's Medicin...
GSK secures China approval for Blenrep in relapsed multiple myeloma
20 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) declared on Monday that it has received approval from China's National Medical Products Administration for Blenrep (belant...
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
20 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Saturday that its protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), showed statistically sig...
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
20 April 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday reported positive high-level results from the Phase III MIRANDA trial, demonstrating that its IL-3...
TheraCryf advances Ox-1 programme to clinical stage following successful GMP manufacture
20 April 2026 - TheraCryf plc (AIM: TCF), a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, revealed on Monday that it has completed the Good Manufac...
Accent Therapeutics presents ATX-295 data at AACR Annual Meeting 2026
20 April 2026 - Clinical-stage biopharmaceutical company Accent Therapeutics on Friday presented preclinical data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, at the American As...